openPR Logo
Press release

Al in Omics Studies Market 2024-2031 | Exclusive Study Report

04-10-2024 10:40 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: ABNewswire

Al in Omics Studies Market

Al in Omics Studies Market

Al in Omics Studies Market is valued at US$ 633.46 Mn in 2023, and it is expected to reach US$ 5,445.6 Mn by 2031
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Al in Omics Studies Market- (By Offering (Software, Services), By Technology Platform (Sequencing, Epigenomics, Proteomics, Metabolomics, Others), By Application (Oncology, Infectious Diseases, Neurology, Cardiovascular Diseases, Immunology, Others), By End User (Academic and Research Institutes, Biopharmaceutical Company, Others)) Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Al in Omics Studies Market is valued at US$ 633.46 Mn in 2023, and it is expected to reach US$ 5,445.6 Mn by 2031, with a CAGR of 31.2% during the forecast period of 2024-2031.

Request for Sample Pages: [https://www.insightaceanalytic.com/request-sample/2363]

Artificial intelligence (AI) is a potent tool for resolving challenging issues when it comes to processing, analysing, and interpreting omics data and integrating multi-omics and clinical data. AI has made significant strides in several scientific domains in recent years, including drug development, illness diagnostics, protein structure prediction, and interpretation of genetic variants. The market for artificial intelligence in omics studies is expanding gradually and is anticipated to develop significantly throughout the projected period. The main factor propelling the use of AI in omics studies is its capacity to evaluate sizable and intricate omics datasets. AI techniques make it easier for researchers to find patterns in omics data, forecast biomarkers, and derive new biological insights. Further accelerating industry growth are investments in AI technology and favourable regulatory frameworks. The future of precision healthcare is being shaped by these variables together, which are driving the rise of AI applications in omics investigations. Thus, AI has the potential to revolutionize omics studies as well as the healthcare sector as a whole, propelling the market for AI in omics studies worldwide.

List of Prominent Players in the Al in Omics Studies Market

* Thermo Fisher Scientific.
* Agilent Technologies
* Illumina
* BGI Genomics
* Dassault Systemes
* Qiagen
* Waters Corporation
* GE Healthcare
* Amazon Web Services, Inc
* Bruker
* Danaher
* Other Prominent Players

Market Dynamics:

Drivers-

One of the main factors propelling AI in the omics studies market is its enormous potential to revolutionise genomics studies and healthcare. The market for omics studies is seeing an increase in AI due to a number of factors. First, as omics data grows in volume and complexity, sophisticated analytics tools are needed. AI is excellent at processing, analysing, and deriving valuable insights from this data. Second, AI-driven methods for omics-based biomarker identification and medication development are required due to the growing need for tailored medicine and focused therapeutics. Thirdly, partnerships between academic, business, and medical facilities encourage creativity and accelerate the use of AI in omics studies.

Challenges:

The primary obstacles that AI in the omics studies sector must overcome are concerns about data privacy and security. The market development may be hampered by the requirement for more qualified Al experts and a strict regulatory environment. The growing need for Al in many industries, such as genomics, presents formidable obstacles due to the scarcity of Al-versed professionals, impeding market expansion. Due to the intricacy of Al technologies and their use in genomics, a certain set of skills still needs to be improved. This scarcity impedes the smooth incorporation of Al into genomics procedures and decelerates the sequence of progress in the area. Adopting and utilising Al in genomics would also be difficult due to the strict laws controlling data security, privacy, and ethical issues.

Regional Trends:

In 2023, due to the presence of several industry participants, such as Google Health, Danone, Abbott, Nestle, IBM, Targeted Medical Pharma, Inc., LLC, and others, North America held the bulk of the worldwide AI in omics market share of approximately in terms of revenue. Some of the biggest and best-funded research institutes and biotechnology firms in the world are based in North America, and these organisations are actively investing in the development of AI-powered genomics solutions. This helps to fuel AI's expansion in North America's genomics business. It is anticipated that the industry would develop significantly overall in Asia Pacific. The region's enormous population, growing emphasis on precision medicine and genomics technology, and fast rising healthcare costs are driving demand for AI in genomics.

Curious about this latest version of the report? @ [https://www.insightaceanalytic.com/enquiry-before-buying/2363]

Recent Developments:

* In November 2023, biotechnology companies OWKIN and 10x Genomics, Inc., jointly announced that they have reached an agreement to incorporate 10x Genomics' single-cell and spatial omics technologies to their work in tumour investigation for potential therapeutic targets.
* In September 2023, Janssen Global Services, LLC, a pharmaceutical firm, and Intelligent OMICS Ltd., a biotechnology company, agreed to a partnership in AI-driven research. The goal of the partnership with Janssen Global Services, LLC is to identify new biological targets that can be used to treat haematological malignancies.
* in June 2022, the Ultima Genomics firm and Nvidia announced that they are partnering to separate AI at various stages of the DNA sequencing and analysis process. Accelerating variant calling and deep learning in photometry and base calling are two aspects of the relationship.

Segmentation of Al in Omics Studies Market -

By Offering:

* Software
* Services

By Technology Platform:

* Sequencing
* Epigenomics
* Proteomics
* Metabolomics
* Others (Transcriptomics, among others)

By Application:

* Oncology
* Infectious Diseases
* Neurology
* Cardiovascular Diseases
* Immunology
* Others (Pharmacogenomics, among others)

By End User:

* Academic and Research Institutes
* Biopharmaceutical Company
* Others (Contract Research Organizations, among others)

By Region-

North America-

* The US
* Canada
* Mexico

Europe-

* Germany
* The UK
* France
* Italy
* Spain
* Rest of Europe

Asia-Pacific-

* China
* Japan
* India
* South Korea
* Southeast Asia
* Rest of Asia Pacific

Latin America-

* Brazil
* Argentina
* Rest of Latin America

Middle East & Africa-

* GCC Countries
* South Africa
* Rest of Middle East and Africa

For More Customization @ [https://www.insightaceanalytic.com/customisation/2363]

Media Contact
Company Name: InsightAce Analytic Pvt. Ltd
Contact Person: Diana D'Souza
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=al-in-omics-studies-market-20242031-exclusive-study-report]
Country: United States
Website: https://www.insightaceanalytic.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Al in Omics Studies Market 2024-2031 | Exclusive Study Report here

News-ID: 3459307 • Views:

More Releases from ABNewswire

Ophthalmoscopes Market to Reach USD 294.90 Million by 2034, Growing at 5.24% CAGR | Rising Demand for Digital and Direct Ophthalmoscopes Drives Global Expansion, analyses DelveInsight
Ophthalmoscopes Market to Reach USD 294.90 Million by 2034, Growing at 5.24% CAG …
Leading ophthalmoscopes companies in the market include Baxter, HEINE Optotechnik GmbH & CO. KG, Keeler, US Ophthalmic, Rudolf Riester GmbH, Opticlar, Zumax Medical Co., Ltd., Girodmedical, Adam Rouilly Ltd., Timesco Healthcare Ltd., Zhejiang Honsun Medical Technology Co., Ltd., Iridex Corporation, NIDEK CO., Ltd., OSCAR BOSCAROL S.r.l, American Diagnostic Corporation, Lumenis Be Ltd., Veatch Ophthalmic Instruments, KIRCHNER &WILHELM GmbH + Co. KG, oDocs Eye care, Revenio Group, and others. The global ophthalmoscopes
RINVOQ Market Growth Accelerates Across IBD, Dermatology, and Rheumatology as Global Sales Momentum Strengthens | DelveInsight
RINVOQ Market Growth Accelerates Across IBD, Dermatology, and Rheumatology as Gl …
The global immunology market is witnessing a significant transformation as RINVOQ (upadacitinib) continues to demonstrate strong prescription growth, expanding indications, and robust revenue performance. DelveInsight's "RINVOQ Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of RINVOQ for approved indications like Ankylosing Spondylitis, Atopic Dermatitis, Axial SpA, Crohn's Disease, Giant Cell Arteritis, Psoriatic Arthritis, Rheumatoid Arthritis, and Ulcerative Colitis; as well as potential indications like Alopecia Areata, Hidradenitis
Prostate Cancer Competitive Landscape Analysis 2026: Clinical Trial Trends, Novel Therapies, Regulatory Milestones, and Future Outlook | DelveInsight
Prostate Cancer Competitive Landscape Analysis 2026: Clinical Trial Trends, Nove …
Leading Prostate Cancer companies include Merck & Co., Inc., Telix Pharmaceuticals Limited, Exelixis, Inc., AstraZeneca PLC, Pfizer Inc., Bristol-Myers Squibb Company, AbbVie Inc., BeiGene, Ltd., and Ipsen S.A., among many others-are actively developing next-generation therapies to reshape the treatment landscape. The treatment paradigm for prostate cancer is witnessing rapid transformation, with more than 150 companies advancing innovative drug candidates across diverse clinical phases. Recent milestones include multiple FDA fast-track designations, companion
Electrosurgical Devices Market to Reach USD 10,220.04 Million by 2034, Growing at 6.34% CAGR | DelveInsight
Electrosurgical Devices Market to Reach USD 10,220.04 Million by 2034, Growing a …
Electrosurgical Devices Companies in the market include B. Braun Melsungen AG, ConMed Corporation, Olympus Corporation, Apyx Medical Corporation, Medtronic, Johnson & Johnson, Smith & Nephew Plc, Erbe Elektromedizin GmbH, KLS Martin Group, BOWA-electronic GmbH & Co. KG, Modern Medical, Kirwan Surgical Products, LLC, Utah Medical Products, Inc., Hangzhou AGS MedTech Co., Ltd., New Deantronics Taiwan Ltd., Parkell, Inc., Surgical Holdings, CIMPAX, Boston Scientific Corporation, and Others The global electrosurgical devices market

All 5 Releases


More Releases for Omics

Single-Cell Omics Market to Reach USD 10.74 Billion by 2030 as Multi-Omics & Pre …
Sub-Headline: The global Single-Cell Omics Market is expected to grow from USD 4.12 billion in 2023 to USD 10.74 billion by 2030, registering a robust CAGR of 14.6%, driven by rapid advances in single-cell sequencing, spatial omics, immunology research, and multi-omics integration. Introduction The Single-Cell Omics Market is undergoing explosive expansion as researchers seek deeper insights into cellular diversity, gene expression variability, epigenetic signatures, and molecular activity at single-cell resolution. Unlike bulk
Emerging Single-Cell Omics Market Trends: Product Innovation Marks A Milestone I …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Single-Cell Omics Market Size Growth Forecast: What to Expect by 2025? The size of the single-cell omics market has experienced rapid expansion in the last few years. From the year 2024 to 2025, an increase from $2.08 billion to $2.39 billion is projected, with an anticipated compound annual growth
Rising Cancer Prevalence Propels Growth In The Single-Cell Omics Market: An Emer …
The Single-Cell Omics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Projected Growth of the Single-Cell Omics Market? In recent times, there has been a significant expansion in the size of the single-cell omics market. It is predicted to increase from $2.08 billion
Rising Prevalence Of Genetic Illnesses Drives Growth Of The Spatial Omics Market …
What combination of drivers is leading to accelerated growth in the spatial omics market? The rising prevalence of genetic disorders is expected to drive the spatial omics market. Genetic diseases are caused by abnormalities in DNA and are increasing due to better awareness and diagnostic technologies. Spatial omics provides in-depth molecular and genetic maps, helping study these disorders. For instance, the World Health Organization (WHO) estimated that congenital diseases caused 240,000
Prominent Single-Cell Omics Market Trend for 2025: Product Innovation Marks A Mi …
What industry-specific factors are fueling the growth of the single-cell omics market? The escalation in the occurrence of cancer is forecasted to boost the expansion of the single-cell omics market in the future. Cancer includes various diseases that occur when irregular cells multiply uncontrollably, overstep their usual limits, and either metastasize to other organs or infiltrate nearby body parts in almost any organ or tissue. The detection of biomarkers for cancer
Charnwood Discovery and Intelligent Omics Announce Strategic Collaboration
Charnwood Discovery a leading drug discovery research partner has announced a strategic collaboration with Intelligent OMICS Ltd (Intellomx) who specialise in applying artificial intelligence (AI) and Machine Learning (ML) to accelerate drug discovery. The collaboration will enable Charnwood Discovery to enhance its already extensive drug discovery services through Intellomx's AI platform which enables the identification of previously unattainable targets. Dr Francesca Sadler, Charnwood Discovery's Chief Commercial Officer commented: "This exciting collaboration